Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
P/S ratio for Janux Therapeutics, Inc. (JANX)
P/S ratio as of 2023: 58.43
According to Janux Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 58.43. At the end of 2022 the company had a P/S ratio of 63.42.
P/S ratio history for Janux Therapeutics, Inc. from 2019 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 58.43 |
| 2022 | 63.42 |
| 2021 | 223.74 |
| 2020 | 0.00 |
| 2019 | 0.00 |